1.AIDS and the community
Papua New Guinea medical journal 1996;39(3):214-217
PIP: HIV/AIDS is transmitted in developing countries mainly through heterosexual sexual intercourse, and from mothers to babies. While the AIDS pandemic could actually reverse population growth in developing countries, it remains to be seen what future population growth trends will emerge. There are, however, current economic and personal costs to both countries and communities. HIV/AIDS has most severely affected the young, economically productive generations, and decimated some village populations in countries heavily dependent upon agriculture. 85% of Papua New Guinea's population lives in villages and depends upon their own labor for food. Other direct effects of HIV/AIDS upon communities are discussed, including the vertical transmission of HIV and the association of HIV/AIDS with other sexually transmitted diseases and tuberculosis. Fear and ignorance are discussed with regard to how communities have responded to HIV/AIDS, followed by consideration of strategies communities may use to deal with HIV/AIDS, the challenge to survive, and the interdependence of community and the individual.
Acquired Immunodeficiency Syndrome - epidemiology
;
Acquired Immunodeficiency Syndrome - prevention &
;
control
;
Community Participation - methods
;
Papua New Guinea - epidemiology
;
Primary Prevention - methods
3.Progress in research on HIV cluster detection and response.
Huan Chang YAN ; Yu LIU ; Shi Xing TANG ; Jing GU ; Yuan Tao HAO
Chinese Journal of Epidemiology 2023;44(4):677-682
HIV cluster detection and response (CDR) is a critical strategy to end the HIV epidemic by offering information to identify prevention and care services gaps. The risk metrics for HIV clusters can be classified into three groups: growth-based metrics, characteristic-based metrics, and phylogeny-based metrics. When identifying HIV risk clusters, the public health response can reach people in the affected networks, including people with undiagnosed HIV, people with diagnosed HIV who might not be accessing HIV care or other services, and people without HIV who would benefit from prevention services. To provide references for HIV precise prevention in China, we summarized the risk metrics and the intervention measures for CDR.
Humans
;
HIV Infections/prevention & control*
;
Acquired Immunodeficiency Syndrome/epidemiology*
;
Public Health
;
Epidemics/prevention & control*
;
China/epidemiology*
5.Prevention and control of HIV/AIDS in China: lessons from the past three decades.
Jun-Jie XU ; Meng-Jie HAN ; Yong-Jun JIANG ; Hai-Bo DING ; Xi LI ; Xiao-Xu HAN ; Fan LV ; Qing-Feng CHEN ; Zi-Ning ZHANG ; Hua-Lu CUI ; Wen-Qing GENG ; Jing ZHANG ; Qi WANG ; Jing KANG ; Xiao-Lin LI ; Hong SUN ; Ya-Jing FU ; Ming-Hui AN ; Qing-Hai HU ; Zhen-Xing CHU ; Ying-Jie LIU ; Hong SHANG
Chinese Medical Journal 2021;134(23):2799-2809
In the past 37 years, human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) has undergone various major transmission routes in China, with the world most complex co-circulating HIV-1 subtypes, even the prevalence is still low. In response to the first epidemic outbreak of HIV in injecting drug users and the second one by illegal commercial blood collection, China issued the Anti-Drug Law and launched the Blood Donation Act and nationwide nucleic acid testing, which has avoided 98,232 to 211,200 estimated infections and almost ended the blood product-related infection. China has been providing free antiretroviral therapy (ART) since 2003, which covered >80% of the identified patients and achieved a viral suppression rate of 91%. To bend the curve of increasing the disease burden of HIV and finally end the epidemic, China should consider constraining HIV spread through sexual transmission, narrowing the gaps in identifying HIV cases, and the long-term effectiveness and safety of ART in the future.
Acquired Immunodeficiency Syndrome/prevention & control*
;
China/epidemiology*
;
Disease Outbreaks
;
HIV Infections/prevention & control*
;
Humans
;
Prevalence
6.Comprehensive evaluation of AIDS spending in Dehong prefecture of Yunnan province in 2010.
Duo SHAN ; Jiang-ping SUN ; Yakusik ANNA ; Zhong-dan CHEN ; Jian-hua YUAN ; Tao LI ; Guang ZHANG ; Xing YANG ; Mei WEI ; Song DUAN ; Li-fen XIANG ; Run-hua YE ; Yue-cheng YANG
Chinese Journal of Preventive Medicine 2013;47(11):991-995
OBJECTIVETo comprehensive evaluate the rationality of Acquired Immune Deficiency Syndrome (AIDS) expenditure through the analysis of AIDS expenditure circumstances based on the application of National AIDS Spending Assessment in Dehong prefecture in 2010.
METHODSDemographic and economic indicators of Mang City, Yingjiang, Longchuan, Ruili City, Lianghe and Wanting zone in Dehong prefecture of Yunnan province were collected from the reports issued by Dehong Statistical Bureau of 2010, and HIV/AIDS epidemic indicators were collected from the annual report of national AIDS prevention and control data.NASA method was used to analyze the actual spending and demand index was used to calculate the demand of AIDS funding in these counties (cities). The correlations between HIV/AIDS expenditures and demographic, economic and HIV/AIDS epidemic index were analyzed, respectively, as well as the correlation between the expenditures of AIDS prevention and control and proportion of major transmission approaches.
RESULTSIn 2010, the actual expenditures on HIV/AIDS in the 5 counties (cities) of Dehong prefecture was ¥28 752 772, the population was 1 211 400, and Gross Domestic Product (GDP) was ¥11 693. The intervention expenditures in injection drug users, sexually transmitted people, and prevention of mother to child transmission in Ruili county were ¥130 345, ¥71 484 and ¥164 100, the proportions of HIV transmission in these groups were 23.9% (49/205), 73.7% (151/205), and 0.5% (1/205), respectively; and in Lianghe county was ¥141 665, ¥257 142, and ¥99 961, and the proportions of HIV transmission were 17.1% (6/35), 80.0% (28/35) and 0.0% (0/35), respectively. The intervention expenditures in Ruili and Lianghe counties were positive related to the proportion of corresponding people with HIV infection (both r values were 0.99, all P values < 0.05). In the other 4 counties (cities) and the development zone, no correlations. The expenditures of government departments, international projects, domestic research programs and personal and family pays (r value were 0.94, 0.83, 0.99 and 0.88, respectively, all P values < 0.05) were positive related to the number.Except the personal and family pays, other sources of expenditures were all positive related to the number of reported HIV/AIDS cases (r values were 0.94, 0.89 and 0.81, respectively, all P values < 0.05).
CONCLUSIONPopulation and HIV/AIDS epidemic index were considered as factors in AIDS spending. The expenditures corresponded with the demand of different areas basically.
Acquired Immunodeficiency Syndrome ; economics ; epidemiology ; prevention & control ; China ; epidemiology ; Health Expenditures ; Humans
10.Key quality indicators of the China Comprehensive AIDS Response 2008 - 2011 Program.
Di WU ; Heng ZHANG ; Xin-lei YAO ; Yan CUI
Chinese Journal of Preventive Medicine 2012;46(12):1095-1098
OBJECTIVETo analyze the key indicators of China Comprehensive AIDS Response Program (China CARES) and the effects of this program during 2008 and 2011.
METHODSData were obtained from National AIDS Comprehensive Prevention and Control Information System. The general population HIV test rate and spouse of people living with HIV or AIDS (PLWHA) HIV test rate were chosen as the indicators for HIV testing expansion; anti-retroviral therapy (ART) coverage and PLWHA CD4 test rate during the past 6 months as the indicators for treatment expansion; femal sex worker (FSW) intervention coverage and injection drug users (IDU) intervention coverage as the Indicators for behavior intervention expansion. The Key working quality indicators of 309 program sites were calculated and the results were compared.
RESULTSDuring 2008 and 2011, for China CARES, the Median of general population HIV test rate were 1.8%, 2.5%, 3.2% and 5.5%, the Median of spouse of PLWHA HIV test rate were 80.9%, 85.7%, 91.8% and 100.0%, the Median of ART coverage were 60.0%, 66.7%, 76.1% and 92.0%, the Median of PLWHA CD4 test rate during the past 6 months were 27.7%, 45.4%, 58.6% and 75.3%, the Median of FSW intervention coverage were 43.8%, 67.8%, 73.3% and 90.9%, the Median of IDU intervention coverage were 18.2%, 24.0%, 34.0% and 72.4%. The indicators of China CARES increased steadily from 2008 to 2011 in HIV testing expansion, treatment expansion and behavior intervention expansion; Compared to 2008, the percentage of the China CARES which had great progress of the 6 indicators were 98.4% (304/309), 98.3% (286/291), 94.0% (281/299), 93.5% (288/308), 91.8% (279/304) and 90.0% (223/247). in 2008, 3 indicators which were ART coverage, PLWHA CD4 test rate during the past 6 months and FSW intervention coverage were lower than national average (6.9%, 17.9% and 30.9%), the general population HIV test rate, spouse of PLWHA HIV test rate and IDU intervention coverage were higher than national average (3.4%, 64.3% and 22.8%), with the China CARES project going on, in 2011, key indicators which were general population HIV test rate, spouse of PLWHA HIV test rate, ART coverage, PLWHA CD4 test rate during the past 6 months, FSW intervention coverage and IDU intervention coverage were all higher than national average (6.5%, 80.6%, 81.9% and 55.9%).the proportions of China CARES sites whose 6 indicators were higher than national average in 2008 were 32.7% (101/309), 60.6% (149/246), 37.4% (99/265), 61.1% (181/296), 64.0% (174/270) and 45.3% (73/161), and the proportions increase annually to 2011 were 44.0% (136/309), 89.3% (260/291), 76.6% (229/299), 77.9% (240/308), 91.4% (278/304) and 64.8% (160/247).
CONCLUSIONAn obvious achievements have been made in the areas of HIV/AIDS prevention and control among China CARES sites during 2008 and 2011 than the national average.
Acquired Immunodeficiency Syndrome ; drug therapy ; epidemiology ; prevention & control ; Anti-Retroviral Agents ; therapeutic use ; China ; epidemiology ; Humans ; Quality Indicators, Health Care